Merck & Co., Inc. or United Therapeutics Corporation: Who Invests More in Innovation?

Merck vs. United Therapeutics: A Decade of R&D Investment

__timestampMerck & Co., Inc.United Therapeutics Corporation
Wednesday, January 1, 20147180000000242549000
Thursday, January 1, 20156704000000245098000
Friday, January 1, 20167194000000147600000
Sunday, January 1, 20179982000000264600000
Monday, January 1, 20189752000000357900000
Tuesday, January 1, 201998720000001182600000
Wednesday, January 1, 202013397000000357700000
Friday, January 1, 202112245000000540100000
Saturday, January 1, 202213548000000322900000
Sunday, January 1, 202330531000000408000000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: A Tale of Two Giants

In the ever-evolving pharmaceutical industry, innovation is the lifeblood that drives progress. Merck & Co., Inc. and United Therapeutics Corporation are two titans in this field, each with a unique approach to research and development (R&D) investment. Over the past decade, Merck has consistently outpaced United Therapeutics in R&D spending, with a staggering 4,200% more investment in 2023 alone. This trend highlights Merck's commitment to pioneering new treatments and therapies. From 2014 to 2023, Merck's R&D expenses surged by over 300%, reflecting its aggressive strategy to maintain a competitive edge. In contrast, United Therapeutics has shown a more modest increase, focusing on niche innovations. This disparity underscores the diverse strategies within the pharmaceutical sector, where both companies aim to transform healthcare, albeit on different scales.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025